GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearside Biomedical Inc (FRA:CLM) » Definitions » Debt-to-Revenue

Clearside Biomedical (FRA:CLM) Debt-to-Revenue : 0.57 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Clearside Biomedical Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Clearside Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.36 Mil. Clearside Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.31 Mil. Clearside Biomedical's annualized Revenue for the quarter that ended in Dec. 2024 was €1.17 Mil. Clearside Biomedical's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.57.


Clearside Biomedical Debt-to-Revenue Historical Data

The historical data trend for Clearside Biomedical's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearside Biomedical Debt-to-Revenue Chart

Clearside Biomedical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.02 0.97 0.12 0.42

Clearside Biomedical Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 1.02 2.39 0.19 0.57

Competitive Comparison of Clearside Biomedical's Debt-to-Revenue

For the Biotechnology subindustry, Clearside Biomedical's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearside Biomedical's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Debt-to-Revenue falls into.


;
;

Clearside Biomedical Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Clearside Biomedical's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.358 + 0.313) / 1.589
=0.42

Clearside Biomedical's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.358 + 0.313) / 1.168
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Clearside Biomedical Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Clearside Biomedical's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Clearside Biomedical Business Description

Traded in Other Exchanges
Address
900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Clearside Biomedical Headlines

From GuruFocus

Cornerstone Funds Announce Continuing Monthly Distributions

By GuruFocusNews GuruFocusNews 07-02-2022

Cornerstone Strategic Value Fund Inc's Dividend Analysis

By GuruFocus Research 10-12-2023

Cornerstone Funds Announce Continuing Monthly Distributions

By GuruFocusNews GuruFocusNews 05-23-2022

Cornerstone Funds Announce Continuing Monthly Distributions

By Marketwired Marketwired 05-09-2020

Cornerstone Funds Announce Continuing Monthly Distributions

By Marketwired Marketwired 05-07-2021

Cornerstone Funds Announce Continuing Monthly Distributions

By GuruFocusNews GuruFocusNews 02-14-2022

Cornerstone Funds File Their Annual Reports

By GuruFocusNews GuruFocusNews 03-02-2022

Cornerstone Funds File Their Annual Reports

By Marketwired Marketwired 02-29-2020